Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 313atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

NCT02482428 2021-01-05

Efficacy and Tolerability of Topical LFX453 for External Genital Warts

Novartis

Phase 2 Completed
88 enrolled 10 charts

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡